Gilead’s (GILD) Blockbuster Hepatitis-C Drug Sovaldi Steps Up Race

Meng Meng | |

In early March, shares of Gilead ($GILD) notched a five-year-high of $84.88 per share thanks to the company’s Hepatitis C super drug Sovaldi. Costing $1,000 for a single tablet, Sovaldi

Blockchain in Fintech - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Financial Market Infrastructure


Sohn Investment Conference

Wall Street’s best and brightest investors participate in this unique, “must attend” event to share their expertise with an audience of more than 3,000 people, comprised of portfolio managers, asset…

Learn more